Mr. Y. Mark Xu is the Co-founder, Chairman, CEO and President of Xynomic Pharmaceuticals, Inc. Mr. Xu is a successful Silicon Valley-China serial entrepreneur. During 2005-2009 Mr. Xu co-founded Bridge Labs and Pacific Biopharma Group, which merged with Pharmacyclics in 2009. Mr. Xu, through these 2 ventures, generated ~RMB 2.5 billion for co-founders and investors. During 2009-2016 Mr. Xu served as the Greater China General Manager of Trout Group, the largest investment bank and advisory firm in the US focusing exclusively on serving small-to-mid sized life sciences companies. Before 2005 Mr. Xu held progressive positions in the US at leading MNCs including Schering, McKesson (world’s largest pharmaceutical distribution company), Stanford Research Institute International, BAS, and UL. Mr. Xu holds a MBA from Stanford University, a MS in Chemistry from Purdue University and a BA in Chemistry (Magna Cum Laude) from Hanover College.
Jason Wu, Ph.D.
Chief Operating Officer
Dr. Wu has over 20 years of working experience in pharmaceutical industry in US and China. He held senior management positions in a number of pharmaceutical companies and research institutes, including Lilly, Merck, Hutchison Medi Pharma, and Institute of Materia Medica. He has a PhD from Purdue University. Dr. Wu is an adjunct professor at the Institute of Materia Medica (IMM) of the Chinese Academy of Medical Science (CAMS). Dr. Wu has been working as a consultant for Chinese and western life sciences companies since 2012, advising clients on technology transfer, licensing, and M&A activities.
Dr.Yong Cui, Ph.D.
Vice President of CMC
Dr. Cui has 18 years’ working experience in pharmaceutical industry in US and China. He obtained his BS and MS degrees from China Pharmaceutical University (1991 and 1994) and worked there for five years before attending Ohio State University for his PhD training (1999-2003). After graduation Dr. Cui joined Vertex Pharmaceuticals (Boston) as a formulation scientist (2003-2005). He then moved to Genentech as a formulation scientist and later moved up to become a Group Leader/Senior Scientist (2005-2013). In 2013 Dr. Cui joined Hisun-Pfizer Pharmaceuticals (Shanghai) as a Director of Formulation Development. In 2015 he joined Qilu Pharmaceuticals (Hainan) as a Vice President of R&D and Business Development of US.Dr. Cui’s experience covers both new chemical entities and generic products. He is the lead pharmaceutical scientist for two successful NDAs in the US, and has been involved in multiple interactions with the US FDA. He has been an invited expert by China FDA since 2012. Dr. Cui’s research interests include late-stage drug product development and pharmaceutical material science. He has authored or co-authored 20 publications.
Xuexun Fang, Ph.D.
Head of Pharmacology
Dr.Fang was formerly Vice General Manager of Dual Pharma China. Dr. Fang earned his Ph.D. in Molecular Biology and Biochemistry from University of West Virginia and BS in Biochemistry from Jilin University, China. Dr. Fang also did post-doctoral research from 1997-2002 at the Sanford Burnham Prebys Medical Discovery Institute in La Jolla, California, USA.
Vice President of Global Strategic Sourcing
Chasey has more than 20 years experience in the pharmaceutical industry in the United States, Singapore, China and other APAC countries. Before joining Xynomic Pharma, Chasey held senior management positions in alliance management, supply chain management, and business development at Bristol-Myers Squibb, Clearstone Central Laboratory (acquired by LabCorp), World Courier, and an international CRO.
Chasey is a Registered Pharmacist with a BS in Pharmacy & Pharmacology from The Second Military Medical University of China and an MBA from Drexel University. She also holds a post MBA certification from Rutgers University focusing on pharmaceutical management and a CPIM (Production and Inventory Management) certification, the globally-recognized certification for supply chain management professionals.
Director of Project Management
Shiwen has more than 10 years’ experience in the pharmaceutical industry. His expertise ranges from drug research and development, registration to patent filing. Before joining Xynomic Pharma, He led the successful efforts for the registration of several TCM, including Two Categories II new drugs. He also completed a number of patent filings. He received both his MD and BS from Peking University School of Pharmaceutical Sciences, majoring in natural medicinal chemistry.
Line Zhang, Ph. D.
Senior Director of Pharmaceutical Development
Dr. Zhang has more than 6 years’ experience in pharmaceutical industry. Before joining Xynomic Pharma, Dr. Zhang worked in R&D department in Pfizer and PPD. He led generic drug projects (from inception to ANDA), and also an expert in API process development to cGMP.
He obtained his MS degree from East China University of Science and Technology. After that he achieved his PhD in Nanyang Technological University.
Dr. Yuankai SHi
Dr. Yuankai Shi is the vice president of Cancer Hospital, Chinese Academy of Medical Sciences, the director of cancer center, professor, doctoral advisor, the vice president of Chinese Society of Hematology , Chinese Medical Association , the deputy editor of Chinese Journal of Oncology, a member ofUICC-Union for International Cancer Control, the director of Chinese anti-cancer association, Beijing Association for Medical Education, the CFDA reviewer, the deputy editor of Journal of leukemia & lymphoma , a member of editorial board for more than ten other international and domestic medical magazines, a member of American Society of Clinical Oncology, American Society of Hematology, Asia Clinical Oncology Association.